NEW YORK (GenomeWeb News) – A researcher at the Translational Genomics Research Institute has received a $150,000 grant from the American Cancer Society to identify potential targets of value in fighting acute myeloid leukemia (AML).
James Bogenberger, a researcher in TGen's Leukemia Research Team, will use the three-year grant to fund studies that will identify therapeutic targets that sensitize AML to epigenetic therapies, TGen said on Wednesday.
AML is a malignancy in white blood cells that fight infections, and it is the most common and deadliest form of acute adult leukemia. Because AML is caused by a progression of multiple cellular processes, this TGen project will seek to identify targets that inhibit it in combination with drugs that are already approved by the Food and Drug Administration.
Bogenberger's research will search for genes that, when silenced, may be used to increase the potency of these available epigenetic therapies.